Engage Therapeutics is a pharmaceutical company dedicated exclusively to the epilepsy community. We are developing Staccato Alprazolam, the first epilepsy rescue therapy of its kind that has the ability to stop ongoing seizures.
Employees: 1-10
Total raised: $23M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Lumira Ven... | lumiravent... |
| - | LifeSci Ve... | lifesciven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.09.2017 | Series A | $23M | Lumira Ven... |
Mentions in press and media 8
| Date | Title | Description |
| 12.03.2020 | Engage Therapeutics’ Phase 2b StATES Study Meets Primary Endpoint | SUMMIT, N.J. (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATE... |
| 12.03.2020 | CureVac founder back at the helm; Merck extends immunomodulatory drug discovery program with Sutro | → Daniel Menichella, the CEO of CureVac and the face of its recent endeavors to develop an mRNA vaccine against Covid-19, is stepping down. Founder Ingmar Hoerr is back in charge; the transition happens just days after Meni... |
| 08.05.2019 | Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting | SUMMIT, N.J., May 6, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people with epilepsy who experience a predictable pattern of ... |
| 14.03.2019 | Engage Therapeutics Inc. to Present Phase 2b Data from StATES Study at 2019 American Academy of Neurology Annual General Meeting | SUMMIT, N.J. (PRNewswire) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience a predictable pattern of epileptic seizures, today a... |
| 27.09.2017 | Engage Therapeutics Announces $23 Million Series A | - |
| 27.09.2017 | Lumira Capital Joins $23M Series A for Engage Therapeutics | SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million S... |
| 27.09.2017 | Engage Therapeutics Announces $23M Series A | SUMMIT, NJ, Clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced closing of its $23M Series A financing round. >> Click here for more funding ... |
| 27.09.2017 | Engage Therapeutics Announces $23 Million Series A Financing | SUMMIT, N.J.--(BUSINESS WIRE)--Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million S... |